INTEGRATION OF CLINICAL AND LABORATORY INDICATORS IN THE ASSESSMENT OF INFLAMMATORY ACTIVITY
- Authors
-
-
Nabieva D. A.
Tashkent State Medical University, Tashkent, Uzbekistan
Author
-
- Keywords:
- Rheumatoid arthritis; inflammatory activity; clinical indicators; laboratory markers; disease activity assessment; remission; composite indices
- Abstract
-
Accurate assessment of inflammatory activity is a key component in the management and monitoring of rheumatoid arthritis, as it directly influences therapeutic decision-making and long-term outcomes. In recent years, increasing attention has been given to integrated approaches that combine clinical indicators with laboratory markers to improve the precision of disease activity evaluation. This study aimed to analyze the scientific basis and clinical relevance of integrating clinical and laboratory indicators in the assessment of inflammatory activity in patients with rheumatoid arthritis. The methodology was based on composite assessment principles widely used in international rheumatological research. Clinical indicators included tender and swollen joint counts using the 28-joint system, while laboratory evaluation focused on C-reactive protein as an acute-phase marker of inflammation. Patient-reported and physician global assessments were also incorporated to capture subjective components of disease activity. Remission and minimal disease activity were defined using strict integrated criteria, and their prognostic significance was evaluated in relation to radiographic stability and functional outcomes. The results demonstrated that remission defined by integrated clinical and laboratory criteria was strongly associated with lower residual disease activity, improved structural stability, and better functional preservation during follow-up. In contrast, assessment approaches based solely on clinical or laboratory parameters were less effective in identifying true disease remission. The findings confirm that integrated assessment provides higher predictive value and practical relevance in routine rheumatological practice.
- References
-
1.
Aletaha D., Funovits J., Keystone E.C., Smolen J.S. Disease activity indices in rheumatoid arthritis: which one to use in clinical practice? Clinical and Experimental Rheumatology, 2007, Vol. 25, Suppl. 46, pp. S24–S31.
2.
Aletaha D., Nell V.P.K., Stamm T. et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis. Arthritis Research & Therapy, 2005, Vol. 7, No. 4, pp. R796–R806.
3.
Aletaha D., Smolen J.S. Diagnosis and management of rheumatoid arthritis: A review. JAMA, 2018, Vol. 320, No. 13, pp. 1360–1372.
4.
Aletaha D., Smolen J.S. Remission in rheumatoid arthritis: missing objectives by using inadequate disease activity measures. Arthritis & Rheumatism, 2008, Vol. 58, No. 1, pp. 9–11.
5.
Aletaha D., Smolen J.S. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI). Clinical and Experimental Rheumatology, 2005, Vol. 23, Suppl. 39, pp. S100–S108.
6.
Emery P., Breedveld F.C., Hall S. et al. Comparison of methotrexate monotherapy with combination therapy. New England Journal of Medicine, 2000, Vol. 343, No. 22, pp. 1594–1602.
7.
Felson D.T., Smolen J.S., Wells G. et al. American College of Rheumatology/European League Against Rheumatism preliminary definition of remission in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2011, Vol. 70, No. 3, pp. 404–413.
8.
Fries J.F., Spitz P., Kraines R.G., Holman H.R. Measurement of patient outcome in arthritis. Arthritis & Rheumatism, 1980, Vol. 23, No. 2, pp. 137–145.
9.
Machado P., Castrejon I., Katchamart W. et al. Multinational evidence-based recommendations on how to report disease activity in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2015, Vol. 74, No. 6, pp. 1063–1070.
10.
Pincus T., Yazici Y., Sokka T. Quantitative measures in rheumatic diseases. Clinical and Experimental Rheumatology, 2005, Vol. 23, Suppl. 39, pp. S1–S3.
11.
Prevoo M.L.L., van ’t Hof M.A., Kuper H.H. et al. Modified disease activity scores that include twenty-eight–joint counts. Arthritis & Rheumatism, 1995, Vol. 38, No. 1, pp. 44–48.
12.
Smolen J.S., Aletaha D. Scores for all seasons: SDAI and CDAI. Clinical and Experimental Rheumatology, 2014, Vol. 32, Suppl. 85, pp. S75–S79.
13.
Smolen J.S., Aletaha D., McInnes I.B. Rheumatoid arthritis. The Lancet, 2016, Vol. 388, No. 10055, pp. 2023–2038.
14.
Smolen J.S., Breedveld F.C., Burmester G.R. et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations. Annals of the Rheumatic Diseases, 2016, Vol. 75, No. 1, pp. 3–15.
15.
Smolen J.S., Landewe R., Breedveld F.C. et al. EULAR recommendations for the management of rheumatoid arthritis. Annals of the Rheumatic Diseases, 2020, Vol. 79, No. 6, pp. 685–699.
- Downloads
- Published
- 2026-02-11
- Issue
- Vol. 2 No. 2 (2026)
- Section
- Articles
- License
-
This work is licensed under a Creative Commons Attribution 4.0 International License.
